Hypoxia and B cells
The ability of cells to sense and adapt to changes in oxygen is mediated by hypoxia-inducible factor (HIF). Immune cells function in physiologically complex and varying environments whereby oxygen, pH, nutrients, metabolites and cytokines are continuously fluctuating. HIF is well known to play an im...
Gespeichert in:
Veröffentlicht in: | Experimental cell research 2017-07, Vol.356 (2), p.197-203 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 203 |
---|---|
container_issue | 2 |
container_start_page | 197 |
container_title | Experimental cell research |
container_volume | 356 |
creator | Burrows, Natalie Maxwell, Patrick Henry |
description | The ability of cells to sense and adapt to changes in oxygen is mediated by hypoxia-inducible factor (HIF). Immune cells function in physiologically complex and varying environments whereby oxygen, pH, nutrients, metabolites and cytokines are continuously fluctuating. HIF is well known to play an important role in coordinating the adaptation and function of both innate immune cells and T cells in these complex environments. This review summarises recent discoveries concerning how hypoxia and HIF control B cell behaviour, and regulate antibody quality and decisions concerning tolerance. Hypoxia and HIF activation may provide an important context; coordinating metabolism with variable demands for quiescence, rapid proliferation, and differentiation. Understanding when and how HIF is activated during B cell development and response is important as drugs targeting HIF could influence antibody responses, providing novel therapeutic opportunities for vaccine adjuvants and in treating autoimmunity. |
doi_str_mv | 10.1016/j.yexcr.2017.03.019 |
format | Article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22738137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014482717301246</els_id><sourcerecordid>1878180064</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-aa92a573d9c2051d22ffe5098d5df840c969c3f858478c88e65985da315c4abe3</originalsourceid><addsrcrecordid>eNp9kDFPwzAQhS0EoqUwMSKhSiwsCWc7js8DA1RAkSqxwGy5tiNctUmxU9T-exIKjEy3fO_e00fIBYWcAi1vFvnOb23MGVCZA8-BqgMypKAgYwVjh2QIQIusQCYH5CSlBQAg0vKYDBhyAFGyITmf7tbNNpixqd34fmz9cplOyVFllsmf_dwReXt8eJ1Ms9nL0_PkbpZZjrLNjFHMCMmdsgwEdYxVlReg0AlXYQFWlcryCgUWEi2iL4VC4QynwhZm7vmIXO3_NqkNOtnQevtum7r2ttWMSY6Uy4663lPr2HxsfGr1KqR-p6l9s0maokSKAGXRoXyP2tikFH2l1zGsTNxpCrp3phf625nunWngunPWpS5_CjbzlXd_mV9JHXC7B3wn4zP42G_1tfUuxH6qa8K_BV9LiHqR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1878180064</pqid></control><display><type>article</type><title>Hypoxia and B cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Burrows, Natalie ; Maxwell, Patrick Henry</creator><creatorcontrib>Burrows, Natalie ; Maxwell, Patrick Henry</creatorcontrib><description>The ability of cells to sense and adapt to changes in oxygen is mediated by hypoxia-inducible factor (HIF). Immune cells function in physiologically complex and varying environments whereby oxygen, pH, nutrients, metabolites and cytokines are continuously fluctuating. HIF is well known to play an important role in coordinating the adaptation and function of both innate immune cells and T cells in these complex environments. This review summarises recent discoveries concerning how hypoxia and HIF control B cell behaviour, and regulate antibody quality and decisions concerning tolerance. Hypoxia and HIF activation may provide an important context; coordinating metabolism with variable demands for quiescence, rapid proliferation, and differentiation. Understanding when and how HIF is activated during B cell development and response is important as drugs targeting HIF could influence antibody responses, providing novel therapeutic opportunities for vaccine adjuvants and in treating autoimmunity.</description><identifier>ISSN: 0014-4827</identifier><identifier>EISSN: 1090-2422</identifier><identifier>DOI: 10.1016/j.yexcr.2017.03.019</identifier><identifier>PMID: 28300562</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; Adaptive immunity ; Animals ; ANOXIA ; ANTIBODIES ; B cells ; B-Lymphocytes - metabolism ; Cell Differentiation - immunology ; Cell Hypoxia ; COMPLEXES ; DRUGS ; Humans ; Hypoxia ; IMMUNITY ; Lymphocyte Activation - immunology ; LYMPHOKINES ; METABOLISM ; METABOLITES ; NUTRIENTS ; OXYGEN ; Oxygen - metabolism ; PH VALUE ; REVIEWS ; T-Lymphocytes - immunology ; TOLERANCE ; VACCINES</subject><ispartof>Experimental cell research, 2017-07, Vol.356 (2), p.197-203</ispartof><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-aa92a573d9c2051d22ffe5098d5df840c969c3f858478c88e65985da315c4abe3</citedby><cites>FETCH-LOGICAL-c387t-aa92a573d9c2051d22ffe5098d5df840c969c3f858478c88e65985da315c4abe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.yexcr.2017.03.019$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28300562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22738137$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Burrows, Natalie</creatorcontrib><creatorcontrib>Maxwell, Patrick Henry</creatorcontrib><title>Hypoxia and B cells</title><title>Experimental cell research</title><addtitle>Exp Cell Res</addtitle><description>The ability of cells to sense and adapt to changes in oxygen is mediated by hypoxia-inducible factor (HIF). Immune cells function in physiologically complex and varying environments whereby oxygen, pH, nutrients, metabolites and cytokines are continuously fluctuating. HIF is well known to play an important role in coordinating the adaptation and function of both innate immune cells and T cells in these complex environments. This review summarises recent discoveries concerning how hypoxia and HIF control B cell behaviour, and regulate antibody quality and decisions concerning tolerance. Hypoxia and HIF activation may provide an important context; coordinating metabolism with variable demands for quiescence, rapid proliferation, and differentiation. Understanding when and how HIF is activated during B cell development and response is important as drugs targeting HIF could influence antibody responses, providing novel therapeutic opportunities for vaccine adjuvants and in treating autoimmunity.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>Adaptive immunity</subject><subject>Animals</subject><subject>ANOXIA</subject><subject>ANTIBODIES</subject><subject>B cells</subject><subject>B-Lymphocytes - metabolism</subject><subject>Cell Differentiation - immunology</subject><subject>Cell Hypoxia</subject><subject>COMPLEXES</subject><subject>DRUGS</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>IMMUNITY</subject><subject>Lymphocyte Activation - immunology</subject><subject>LYMPHOKINES</subject><subject>METABOLISM</subject><subject>METABOLITES</subject><subject>NUTRIENTS</subject><subject>OXYGEN</subject><subject>Oxygen - metabolism</subject><subject>PH VALUE</subject><subject>REVIEWS</subject><subject>T-Lymphocytes - immunology</subject><subject>TOLERANCE</subject><subject>VACCINES</subject><issn>0014-4827</issn><issn>1090-2422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDFPwzAQhS0EoqUwMSKhSiwsCWc7js8DA1RAkSqxwGy5tiNctUmxU9T-exIKjEy3fO_e00fIBYWcAi1vFvnOb23MGVCZA8-BqgMypKAgYwVjh2QIQIusQCYH5CSlBQAg0vKYDBhyAFGyITmf7tbNNpixqd34fmz9cplOyVFllsmf_dwReXt8eJ1Ms9nL0_PkbpZZjrLNjFHMCMmdsgwEdYxVlReg0AlXYQFWlcryCgUWEi2iL4VC4QynwhZm7vmIXO3_NqkNOtnQevtum7r2ttWMSY6Uy4663lPr2HxsfGr1KqR-p6l9s0maokSKAGXRoXyP2tikFH2l1zGsTNxpCrp3phf625nunWngunPWpS5_CjbzlXd_mV9JHXC7B3wn4zP42G_1tfUuxH6qa8K_BV9LiHqR</recordid><startdate>20170715</startdate><enddate>20170715</enddate><creator>Burrows, Natalie</creator><creator>Maxwell, Patrick Henry</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20170715</creationdate><title>Hypoxia and B cells</title><author>Burrows, Natalie ; Maxwell, Patrick Henry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-aa92a573d9c2051d22ffe5098d5df840c969c3f858478c88e65985da315c4abe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>Adaptive immunity</topic><topic>Animals</topic><topic>ANOXIA</topic><topic>ANTIBODIES</topic><topic>B cells</topic><topic>B-Lymphocytes - metabolism</topic><topic>Cell Differentiation - immunology</topic><topic>Cell Hypoxia</topic><topic>COMPLEXES</topic><topic>DRUGS</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>IMMUNITY</topic><topic>Lymphocyte Activation - immunology</topic><topic>LYMPHOKINES</topic><topic>METABOLISM</topic><topic>METABOLITES</topic><topic>NUTRIENTS</topic><topic>OXYGEN</topic><topic>Oxygen - metabolism</topic><topic>PH VALUE</topic><topic>REVIEWS</topic><topic>T-Lymphocytes - immunology</topic><topic>TOLERANCE</topic><topic>VACCINES</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burrows, Natalie</creatorcontrib><creatorcontrib>Maxwell, Patrick Henry</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Experimental cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burrows, Natalie</au><au>Maxwell, Patrick Henry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypoxia and B cells</atitle><jtitle>Experimental cell research</jtitle><addtitle>Exp Cell Res</addtitle><date>2017-07-15</date><risdate>2017</risdate><volume>356</volume><issue>2</issue><spage>197</spage><epage>203</epage><pages>197-203</pages><issn>0014-4827</issn><eissn>1090-2422</eissn><abstract>The ability of cells to sense and adapt to changes in oxygen is mediated by hypoxia-inducible factor (HIF). Immune cells function in physiologically complex and varying environments whereby oxygen, pH, nutrients, metabolites and cytokines are continuously fluctuating. HIF is well known to play an important role in coordinating the adaptation and function of both innate immune cells and T cells in these complex environments. This review summarises recent discoveries concerning how hypoxia and HIF control B cell behaviour, and regulate antibody quality and decisions concerning tolerance. Hypoxia and HIF activation may provide an important context; coordinating metabolism with variable demands for quiescence, rapid proliferation, and differentiation. Understanding when and how HIF is activated during B cell development and response is important as drugs targeting HIF could influence antibody responses, providing novel therapeutic opportunities for vaccine adjuvants and in treating autoimmunity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28300562</pmid><doi>10.1016/j.yexcr.2017.03.019</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-4827 |
ispartof | Experimental cell research, 2017-07, Vol.356 (2), p.197-203 |
issn | 0014-4827 1090-2422 |
language | eng |
recordid | cdi_osti_scitechconnect_22738137 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | 60 APPLIED LIFE SCIENCES Adaptive immunity Animals ANOXIA ANTIBODIES B cells B-Lymphocytes - metabolism Cell Differentiation - immunology Cell Hypoxia COMPLEXES DRUGS Humans Hypoxia IMMUNITY Lymphocyte Activation - immunology LYMPHOKINES METABOLISM METABOLITES NUTRIENTS OXYGEN Oxygen - metabolism PH VALUE REVIEWS T-Lymphocytes - immunology TOLERANCE VACCINES |
title | Hypoxia and B cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A43%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypoxia%20and%20B%20cells&rft.jtitle=Experimental%20cell%20research&rft.au=Burrows,%20Natalie&rft.date=2017-07-15&rft.volume=356&rft.issue=2&rft.spage=197&rft.epage=203&rft.pages=197-203&rft.issn=0014-4827&rft.eissn=1090-2422&rft_id=info:doi/10.1016/j.yexcr.2017.03.019&rft_dat=%3Cproquest_osti_%3E1878180064%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1878180064&rft_id=info:pmid/28300562&rft_els_id=S0014482717301246&rfr_iscdi=true |